HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...

A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Having asthma, Hashimoto’s thyroiditis or atopic dermatitis in addition to alopecia areata raised the odds for early-onset, severe and prolonged alopecia areata, according to a research letter ...

While there are different forms of alopecia, Cadogan has alopecia areata, which is characterized by circular bald patches on ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...

Two clinical trials tested if Olumiant was effective and safe for people with alopecia areata. The trials included 1,200 people who had severe alopecia areata for more than six months. Most of the ...

HCW Biologics Inc. has received clearance of its IND application from the FDA to initiate a first-in-human phase I trial to ...

HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration ...

According to a recent study, comorbid chronic inflammatory diseases influence the prognosis of alopecia areata.

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...